Belay Diagnostics is redefining how brain and spinal cord cancers are detected. Our advanced cerebrospinal fluid (CSF) testing platforms use next-generation sequencing (NGS) and quantitative polymerase chain reaction (qPCR) to identify genetic mutations, chromosomal abnormalities, and MGMT promoter methylation, providing clinicians and patients with a less invasive alternative to surgical biopsies.
Our unique offerings help inform the diagnosis and management of primary CNS malignancies. We see our technological advances in CSF assays as offering clinicians alternative diagnostic tools for use in treatment decisions, while helping guide patients with a minimally invasive solution.
Company Details
- Employees
- 49
- Founded
- -
- Address
- 1375 W Fulton St,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://belaydiagnostics.com
- Keywords
- Cerebrospinal Fluid (CSF) Liquid Biopsy, Molecular Diagnostic Testing, Clinical Research, Next-Generation Sequencing (NGS) Services, Precision Medicine Support, Clinical Decision Support Tools.
- HQ
- Chicago, Illinois
Belay Diagnostics Questions
Belay Diagnostics's website is http://belaydiagnostics.com
Belay Diagnostics's LinkedIn profile is https://www.linkedin.com/company/belay-diagnostics
Belay Diagnostics has
49 employees.
View email and phone details for 49
employees at Belay Diagnostics.
Belay Diagnostics's industry is
Biotechnology Research
Belay Diagnostics's top competitors are
Tempus Ai,
Xeris Pharmaceuticals, Inc.,
Genomoncology,
Natera,
Vanqua Bio,
Genedx,
Portal Innovations,
Talis Biomedical Corporation,
Mesorna,
Grove Biopharma, Inc..
Belay Diagnostics's categories are Biotechnology Research
Belay Diagnostics's founding year is 2022
